echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol Oncol: Prediction of biochemical recurrence after radical prostatectomy based on T stage based on magnetic resonance imaging

    Eur Urol Oncol: Prediction of biochemical recurrence after radical prostatectomy based on T stage based on magnetic resonance imaging

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Currently, the local stage of prostate cancer (PCa) still relies on digital rectal examination (DRE).

    Therefore, DRE remains the standard for
    risk stratification in guideline recommendations, clinical trials, and patient consultations.
    Over the past 20 years, multiparametric magnetic resonance imaging (mpMRI) has become the most influential diagnostic tool in the PCa Bureau, so the issue is becoming increasingly controversial
    .

    Recently, researchers from Spain published an article in Eur Urol Oncol comparing various T staging models based on DRE or mpMRI for predicting early biochemical recurrence (BCR) after radical prostatectomy (RP).

    The researchers conducted a retrospective multicenter cohort study
    between 2014 and 2021.
    A total of 1,436 patients
    were enrolled in eight referral centres in France, Italy, Switzerland and Belgium.
    BCR is defined as a prostate-specific antigen value of ≥0.
    2 ng/mL
    during two follow-up visits.
    Harrell's Consistency Index (C-index) was used to compare DRE-based (Model 1: CT1 vs cT2 vs cT3) or mpMRI (Model 2: Organ-Localized Disease vs Extracapsular Dilation [iECE] vs Seminal Vesicle Invasion [iSVI]; Model 3: Prostate Imaging-Reporting and Data System [PI-RADS]≤3 vs PI-RADS 4 vs PI-RADS 5; Model 4: iT2a [PI-RADS ≤3] vs iT2b [PI-RADS 4] vs iT2c [PI-RADS 5 excluding ECE or SVI] vs iT3a [ECE] vs iT3b [SVI]) 4 models in predicting BCR
    performance.

    Overall, 74 (5%), 845 (59%), 482 (34%) and 35 (2%) patients had low, intermediate, high, and very high risk PCa
    , according to the Mazzone risk classification.
    After a median follow-up of 16 months, 113 patients experienced BCR
    .
    Although the new mpMRI-based 5-group T staging system (Model 4) has the highest prognostic ability in multivariate analysis to predict early BCR (C index of 0.
    694), there is overlap
    between the 95% confidence intervals of the model.
    In sensitivity analysis, when excluding cN1 patients and comparing with 5 groups of T classification based on DRE (cT1c vs cT2a vs cT2b vs cT2c vs cT3), the new mpMRI-based T staging model still had a higher C index in predicting BCR than DRE, but the 95% confidence intervals for each model still overlapped
    .
    The main limitation of the studies was the short
    follow-up period.

    The performance of four T-staging models in predicting post-RP BCR

    In summary, the researchers elaborated an alternative mpMRI-based T stage that can be used to predict early BCR
    after PCa RP.
    However, the results need to be externally validated before they can be applied to clinical practice

    .

    Original source:

    Michael Baboudjian, Bastien Gondran-Tellier, Alae Touzani et al.
    Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.
    Eur Urol Oncol.
    Oct 2022

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.